DIJON, France – 25 mars 2026 (06.00 PM CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO® ...
Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results